abstract: OBJECTIVES: The aim of the study was the estimation of effect of pelvic and paraaortic lymphadenectomy on intensity of @entity158 complains, and comparison of quantity of @entity260 in groups of @entity1 subjected and not subjected the lymphadenectomy. MATERIAL AND METHODS: We studied to 80 @entity1 divided into two groups: 40 @entity1 with @entity1204 , who were treated with total abdominal hysterectomy, salpingo-oophorectomy and pelvic and paraaortic lymphadenectomy; and 40 @entity1 with uterine @entity1868 or benign neoplasms of uterine adnexa, who were treated with abdominal hysterectomy and salpingo-oophorectomy, but without lymphadenectomy. The measure of intensity of @entity158 complaints was twenty-four hour analgetic requirement of @entity1 in postoperative period, counted by PCA ( @entity1 Controlled Analgesia) pump (Perfusor fm Braun). RESULTS: Twenty-four hour consumption of @entity1286 counted by @entity4901 pump did not statistically differ in both groups of @entity1 . Twenty-four hour consumption of @entity1286 on kilogram of body mass was similarly too. We find 3 (3.8%) intraoperative and 15 (18.8%) @entity260 . The number of complications did not statistical to differ in groups of @entity1 subjected and not subjected lymphadenectomy. CONCLUSIONS: The inclusion of lymphadenectomy into the operation procedures did not increase of @entity158 in the postoperative course. The percentage of @entity260 in both groups was similar. The lymphadenectomy executed in specialised centres of oncological gynaecology is a safe intervention, with a low number of complications.

title: [The effect of pelvic and paraaortic lymphadenectomy on intensity of XXXX and @entity260 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient', 'people']

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['intraoperative and postoperative complications', 'postoperative complications']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: UNASSIGNED: Given the widely varying types of aquatic ecosystems and bioavailability of chemicals, it is important to develop site-specific water quality criteria (WQC) to ensure criteria are neither over- nor under-protective. In the study, using @entity211 ( @entity4426 ) as an example, several approaches to derive site-specific WQC were investigated, including the conventional @entity6128 ( @entity6128 ), weighted @entity6128 based on the proportion of each trophic level, and water effect ratio (WER) method. When corrected to a pH of 7.8, the conventional @entity6128 approach resulted in criteria maximum concentration (CMC) and criteria continuous concentration (CCC) of 18.11 and 1.74 g/L, respectively. If @entity6128 was weighted according to the current species composition in Tai Lake, the CMC and CCC were 32.81 and 4.48 g/L, respectively. However, available data suggest that many sensitive species inhabiting Tai Lake during 1980s were disappeared. Considering the species composition of the healthier ecosystem in 1980s, the CMC and CCC were 10.99 and 0.38 g/L, respectively, which provide more protective water quality standards. Water effect ratio (WER) was further used to correct for co-occurrence of other toxicants and factors affecting bioavailability of @entity4426 . A final WER of 4.72 was applied to adjust the criteria derived by using the weighted @entity6128 for the 1980s aquatic community, and the final CMC and CCC obtained were 51.87 and 1.79 g/L, respectively, at a pH of 7.8. Water quality criteria derived using the 1980s species composition and adjusted with WER were deemed the most appropriate WQC for water management and aquatic life protection. Merits of the various approaches for developing WQC for protection of aquatic species were discussed.

title: Site-specific water quality criteria for aquatic ecosystems: A case study of XXXX for Tai Lake, China.

entities_list: @entity6128 :: ('MESH:D020243', 'Disease') :: ['species sensitivity distribution', 'SSD']

entities_list: @entity211 :: ('MESH:D010416', 'Chemical') :: ['pentachlorophenol']

answer: @entity211 :: (MESH:D010416,Chemical) :: ['pentachlorophenol']


abstract: @entity3852 ( @entity3852 ) is a rare, aggressive @entity1489 with a high potential of locoregional relapse after surgery alone. This report is an update of our experience in the treatment of @entity3852 . From January 1990 to May 2000, 31 @entity1 with @entity3852 , 13 @entity1 and 18 @entity1 aged between 34 and 92 years, were treated at the University of Cologne, Germany. Primary @entity5 sites were in the head and neck region in 13 @entity1 , limbs in 13, and trunk in 5. The @entity5 were stage I in 26 of 31 @entity1 , stage II in 4 of 31 and stage III in 1 of 31. Treatment included surgery alone in 14 of 31 @entity1 , adjuvant postoperative radiotherapy in 16 of 31 @entity1 , 1 of them had incomplete surgery, and definitive radiotherapy in 1 of 31 @entity1 (stage III). Median overall survival (OS) after first diagnosis was 32 months (95% confidence interval: 0-75 months) with a 3-year OS rate of 47% (95% CI: 25-69%). Six of 31 @entity1 relapsed locally after a median of 4 months, 10 of 31 @entity1 developed regional node metastases, and 7 of 31 @entity1 distant metastases. Nine @entity1 died as a direct result of @entity3852 . Locoregional control and disease-free survival were significantly improved in the group with postoperative radiotherapy (p = 0.023). Uni- and multivariate analysis revealed that head and neck location of the @entity5 and the lack of postoperative radiotherapy are unfavorable prognostic factors. Postoperative radiotherapy to the @entity5 region and the regional lymphatics is effective in the prevention of locoregional recurrence. Prospective clinical trials should be performed to confirm these observations.

title: Role of postoperative radiotherapy in the management of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity3852 :: ('MESH:D015266', 'Disease') :: ['MCC', 'Merkel cell carcinoma']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['neuroendocrine tumor of the skin']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumor', 'tumors']

answer: @entity3852 :: (MESH:D015266,Disease) :: ['Merkel cell carcinoma']


abstract: BACKGROUND AND PURPOSE: Cerebrovascular complications are often the first cause of hospitalization in @entity1 with @entity2314 ( @entity2314 ). Screenings for @entity2314 among @entity64 @entity1 have yielded discrepant results, likely as a result of heterogeneous or incomplete assessment. We designed a study to identify @entity2314 among adults 60 years of age or younger who were consecutively admitted for acute @entity385 or @entity63 ( @entity63 ) to a @entity64 neurology service in Italy. METHODS: @entity1 with first-ever or recurrent events were included, irrespective of gender, risk factors, or @entity64 type. We screened male @entity1 using a-galactosidase A enzyme assay, and female @entity1 using DNA sequencing. @entity2314 was eventually established after a broad multidisciplinary discussion. RESULTS: We screened 108 @entity1 (61% males, median age: 48 years); 84% of these @entity1 had @entity64 . De novo @entity2314 diagnosis was established in 3 @entity1 (2.8%; 95% confidence interval, .57-8.18): a 59-year-old @entity1 with recurrent lacunar-like @entity64 and multiple risk factors; a 42-year-old @entity1 with recurrent cryptogenic minor @entity64 ; and a 32-year-old @entity1 with recurrent @entity64 previously attributed to Beh  et's disease. Screened @entity1 were systematically asked for typical @entity2314 symptoms; each of the de novo @entity1 reported one or more of the following: episodes of hand/foot @entity158 during fever, @entity15967 , and family history of @entity299 . In all of the @entity1 events were recurrent, and lacunar-like @entity1188 characterized their brain imaging. CONCLUSIONS: Prevalence of @entity2314 among nonselected adults 60 years of age or younger with acute @entity385 or @entity63 is not negligible. A systematic search for @entity2314 in a @entity64 setting, using a comprehensive clinical, biochemical, and genetic screening protocol, may be worthwhile.

title: De novo Diagnosis of @entity2314 among Italian Adults with Acute XXXX or Transient @entity63 Attack.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'woman', 'patients', 'man']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes', 'stroke']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['transient ischemic attack', 'TIA']

entities_list: @entity2314 :: ('MESH:D000795', 'Disease') :: ['Fabry disease', 'FD']

entities_list: @entity15967 :: ('MESH:D000794', 'Disease') :: ['angiokeratoma']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity385 :: (MESH:D002544,Disease) :: ['Ischemic Stroke']


abstract: BACKGROUND: In the CHAMPION trial, significant reductions in admissions to hospital for @entity712 were seen after 6 months of pulmonary artery pressure guided management compared with usual care. We examine the extended efficacy of this strategy over 18 months of randomised follow-up and the clinical effect of open access to pressure information for an additional 13 months in @entity1 formerly in the control group. METHODS: The CHAMPION trial was a prospective, parallel, single-blinded, multicentre study that enrolled @entity1 with New York Heart Association (NYHA) Class III @entity712 and a previous admission to hospital. @entity1 were randomly assigned (1:1) by centre in block sizes of four by a secure validated computerised randomisation system to either the treatment group, in which daily uploaded pulmonary artery pressures were used to guide medical therapy, or to the control group, in which daily uploaded pressures were not made available to investigators. @entity1 in the control group received all standard medical, device, and disease management strategies available. @entity1 then remained masked in their randomised study group until the last @entity1 enrolled completed at least 6 months of study follow-up (randomised access period) for an average of 18 months. During the randomised access period, @entity1 in the treatment group were managed with pulmonary artery pressure and @entity1 in the control group had usual care only. At the conclusion of randomised access, investigators had access to pulmonary artery pressure for all @entity1 (open access period) averaging 13 months of follow-up. The primary outcome was the rate of hospital admissions between the treatment group and control group in both the randomised access and open access periods. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00531661. FINDINGS: Between Sept 6, 2007, and Oct 7, 2009, 550 @entity1 were randomly assigned to either the treatment group (n=270) or to the control group (n=280). 347 @entity1 (177 in the former treatment group and 170 in the former control group) completed the randomised access period in August, 2010, and transitioned to the open access period which ended April 30, 2012. Over the randomised access period, rates of admissions to hospital for @entity712 were reduced in the treatment group by 33% (hazard ratio [HR] 0  67 [95% CI 0  55-0  80]; p<0  0001) compared with the control group. After pulmonary artery pressure information became available to guide therapy during open access (mean 13 months), rates of admissions to hospital for @entity712 in the former control group were reduced by 48% (HR 0  52 [95% CI 0  40-0  69]; p<0  0001) compared with rates of admissions in the control group during randomised access. Eight (1%) device-related or system related complications and seven (1%) procedure-related adverse events were reported. INTERPRETATION: Management of NYHA Class III @entity712 based on home transmission of pulmonary artery pressure with an implanted pressure sensor has significant long-term benefit in lowering hospital admission rates for @entity712 . FUNDING: St Jude Medical Inc.

title: Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic XXXX therapy: complete follow-up results from the CHAMPION randomised trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure symptoms', 'heart failure']

answer: @entity712 :: (MESH:D006333,Disease) :: ['heart failure']


abstract: Treatment intensification with autologous bone marrow transplantation (ABMT) was administered to 37 cases of Hodgkin's and @entity1893 ( @entity1733 and @entity1893 ) who were in complete or partial remission (CR or PR) after chemotherapy (MOPP/ABVD or F-MACHOP respectively) and to 12 cases of @entity1733 and @entity1893 who were in relapse. ABMT treatment was BAVC for @entity1893 and BEAM for @entity1733 . Marrow cells were harvested from the marrow and cryopreserved. The number of mononuclear marrow cells that was reinfused ranged between 0.19 and 0.80 x 108/Kg b.w. (median 0.39). All the @entity1 were treated with @entity1261 ( @entity1261 , Filgrastim) at a dose of 5 mg/Kg b.w. from day +4 until the absolute neutrophil count exceeded 1 x109/L for 3 consecutive days. Engraftment was observed in all cases, and no transplant-related @entity204 occurred. The @entity1 with @entity1893 and @entity1733 received a median of 12 (range 2-19) and 14.5 (range 9-27) doses of @entity1261 respectively. Median time to 20 x 109/L platelet count was 14 to 17 days. Median time to an absolute neutrophil count 0.5x109/L was 13 days. A febrile episode during the period of post-transplant aplasia was documented in 35 @entity1 (71%). Fever was associated with Gram+ @entity582 in 31% of the cases and with Gram- @entity582 in 11% of cases. @entity281 was documented in two cases. No @entity364 were recorded. Median hospitalisation time from reinfusion ranged between 19.5 days ( @entity1893 ) and 23 days ( @entity1733 ). Thirty-four of 37 cases (92%) who were transplanted in CR or in PR are currently alive and in continuous CR with a median follow-up time of 37 months after ABMT. Three of 12 cases (25%) who were transplanted in relapse are alive and in CR. Our data point out that ABMT followed by @entity1261 is a safe and a very effective procedure for high risk @entity706 , when ABMT is planned and is performed not as a rescue procedure but when it is integrated in the treatment strategy from the very beginning.

title: Treatment intensification of @entity706 with autologous bone marrow transplantation and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte colony stimulating factor']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['malignant lymphomas']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['Herpes Simplex infection']

entities_list: @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal infections']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL']

entities_list: @entity582 :: ('MESH:C531821', 'Disease') :: ['bacteraemia']

answer: @entity1261 :: (1440,Gene) :: ['granulocyte colony stimulating factor']


abstract: BACKGROUND: @entity1149 ( @entity1149 )- @entity1 treated with standard chemotherapy experienced progression rapidly. A novel therapy based on programed death 1 ( @entity8395 )/programed death ligand 1 ( @entity4634 ) inhibitors showed an increasing potential in several @entity5 including advanced @entity1149 . OBJECTIVES: This article is a meta-analysis aiming to systematically evaluate the efficacy and safety profiles of @entity8395 / @entity4634 agents in @entity1 with @entity1149 . DATA SOURCES: Data were collected from eligible studies searched from PubMed, ScienceDirect, and Web of Science. SYNTHESIS METHODS: Pooled hazard ratio (HR) for @entity1349 ( @entity1349 ) and progression-free survival (PFS) was estimated to assess the efficacy of @entity8395 / @entity4634 inhibitors versus @entity1205 , pooled odds ratio (OR) was calculated for objective response rate (ORR). The overall frequency was estimated for 1-year @entity1349 , 1-year progression-free survival, and ORR. A subgroup analysis among @entity1149 @entity1 tested with different @entity470 ( @entity470 ) status was also performed to figure out the relationship between @entity470 status and efficacy of @entity8395 / @entity4634 therapies. OR for occurrence of any grade and grade 3 to 5 treatment-related adverse effect was calculated for evaluating the safety of @entity8395 / @entity4634 therapies. RESULTS: Nine studies were included in this analysis. The pooled HRs for @entity1349 and PFS were 0.68 (95% confidence interval [CI] 0.61-0.75) and 0.83 (95% CI 0.75-0.91), respectively, the pooled OR for ORR was 1.83 (95% CI 1.41-2.36), indicating a significant improvement in @entity1349 , PFS, and ORR. In the results of subgroup analysis, the HR for @entity1349 in @entity1149 @entity1 was 1.05 (95% CI 0.69-1.59) in @entity1 with mutant @entity470 and 0.66 (95% CI 0.57-0.77) in @entity1 with wild-type @entity470 status. OR for occurrence was 0.36 (95% CI 0.28-0.46) in any grade treatment-related adverse effect and 0.18 (95% CI 0.14-0.22) in grade 3 to 5 treatment-related adverse effect, suggesting a superior safety profile of @entity8395 / @entity4634 inhibitors. CONCLUSION: The @entity8395 / @entity4634 therapy significantly prolonged the @entity1349 and improved the ORR, simultaneously lowering the treatment-related adverse effect events versus @entity1205 .

title: A meta-analysis of efficacy and safety of antibodies targeting @entity8395 / XXXX in treatment of advanced @entity1149 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'Nonsmall cell lung cancer']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity4634 :: (29126,Gene) :: ['PD-L1']


abstract: UNASSIGNED: Suboptimal uptake of the measles, mumps and @entity2462 (MMR) vaccine by certain socioeconomic groups may have contributed to recent large measles outbreaks in the UK. We investigated whether socioeconomic deprivation was associated with MMR vaccine uptake over 16 years. Using immunization data for 72 351 @entity1 born between 1995 and 2012 in Liverpool, UK, we examined trends in vaccination uptake. Generalized linear models were constructed to examine the relative effect of socioeconomic deprivation and year of birth on MMR uptake. Uptake of @entity60697 by age 24 months ranged between 82  5% in 2003 [95% confidence interval (CI) 81  2-83  7] and 93  4% in 2012 (95% CI 92  7-94  2). Uptake of @entity54810 by age 60 months ranged between 65  3% (95% CI 64  4-67  4) in 2006 and 90  3% (95% CI 89  4-91  2) in 2012. In analysis adjusted for year of birth and sex, @entity1 in the most deprived communities were at significantly greater risk of not receiving @entity60697 [risk ratio (RR) 1  70, 95% CI 1  45-1  99] and @entity54810 (RR 1  36, 95% CI 1  22-1  52). Higher unemployment and lower household income were significantly associated with low uptake. Contrary to concerns about lower MMR uptake in affluent families, over 16 years, @entity1 from the most socioeconomically deprived communities have consistently had the lowest MMR uptake. Targeted catch-up campaigns and strategies to improve routine immunization uptake in deprived areas are needed to minimize the risk of future measles outbreaks.

title: Effect of socioeconomic deprivation on uptake of measles, mumps and XXXX vaccination in Liverpool, UK over 16 years: a longitudinal ecological study.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

answer: @entity2462 :: (MESH:D012409,Disease) :: ['rubella']


abstract: Excessive @entity2227 transmission in the basal ganglia is a major factor in the neural mechanisms underlying @entity191 . Activation of kappa opioid receptors causes a presynaptic reduction in @entity2227 release. Kappa opioid receptors are concentrated in those regions of the basal ganglia associated with increased @entity2227 transmission in @entity304 . In this study, we use the @entity8490 and @entity2515 -treated @entity35 model of @entity304 to investigate whether systemic administration of the kappa opioid agonists @entity31408 (CI-977) and U69,593 can alleviate the symptoms of @entity304 either alone or in conjunction with @entity935 replacement therapy. We report that, when administered alone, both @entity31408 and U69,593 can increase locomotion in @entity1154 -depleted @entity35 . No @entity2915 was seen after kappa opioid agonist administration in non-parkinsonian @entity35 . The responses to kappa opioid agonists were blocked by co-administration of either the nonspecific opioid receptor antagonist @entity1510 or the selective kappa opioid receptor antagonist @entity14719 ( @entity14719 ). An important finding is that when @entity31408 and L-dopa are administered together, their anti- @entity2845 properties are synergistic. Thus, the doses of @entity31408 and L-dopa required to alleviate @entity910 when administered together are lower than either administered alone. These data illustrate the importance of kappa opioid receptors in the neural mechanisms controlling @entity717 and suggest that kappa opioid agonists may have a role as adjuncts to @entity935 replacement in the management of @entity191 .

title: Kappa-opioid receptor agonists increase locomotor activity in the @entity1154 -depleted @entity35 model of XXXX .

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

entities_list: @entity304 :: ('MESH:D010302', 'Disease') :: ['parkinsonism']

entities_list: @entity2515 :: ('MESH:D012110', 'Chemical') :: ['reserpine']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

entities_list: @entity910 :: ('MESH:D004409', 'Disease') :: ['akinesia']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ['parkinsonian akinesia', "Parkinson's disease"]

entities_list: @entity31408 :: ('MESH:C067110', 'Chemical') :: ['enadoline']

entities_list: @entity1510 :: ('MESH:D009270', 'Chemical') :: ['naloxone']

entities_list: @entity14719 :: ('MESH:C051844', 'Chemical') :: ['nor-BNI', 'nor-binaltorphimine']

entities_list: @entity2915 :: ('MESH:D006948', 'Disease') :: ['increase in locomotor activity']

entities_list: @entity8490 :: ('CHEBI:6912', 'Chemical') :: ['alpha-methyl-p-tyrosine']

entities_list: @entity1154 :: ('CHEBI:25375', 'Chemical') :: ['monoamine']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['voluntary movement']

answer: @entity304 :: (MESH:D010302,Disease) :: ['parkinsonism']


abstract: BACKGROUND: Testing for oncogenic @entity1082 ) DNA at a 1.0-pg/mL threshold represents a promising approach for colposcopy triage of @entity10479 ( @entity10479 ), but not for @entity2784 ( @entity2784 ). Considering age or viral load could improve colposcopy triage. METHODS: We determined the sensitivity for detecting @entity3146 3 (CIN3) and @entity5 and the percentage of referrals for colposcopy using HPV testing and repeat thin-layer cytopathology in 2198 @entity1 with @entity10479 and in 848 @entity1 with @entity2784 enrolled in ALTS from November 1996 through December 1998. We analyzed results by age and at two thresholds for HPV load and repeat cytopathology. RESULTS: For @entity10479 , the overall sensitivity of HPV testing at 1.0 pg/mL was 96.1% (95% confidence interval [CI] = 92.8 to 99.5%) and varied minimally with age (range, 93.9% to 97.8%). HPV testing at this threshold would refer 31.2% (95% CI = 28.0% to 34.3%) of @entity1 aged 29 years or older as compared with more than 65% of younger @entity1 . Among @entity1 aged 29 years or older with @entity10479 , referral for repeat cytopathology of @entity10479 had a sensitivity of 90.9% (95% CI = 81.1% to 100.0%) and would refer 50.1% (95% CI = 46.7 to 53.5%). Among all @entity10479 , HPV testing using a 10.0-pg/mL threshold decreased sensitivity to 91.5% and referrals to 41.7%. More than 63% of @entity2784 would have been referred using any strategy achieving 90% sensitivity. CONCLUSION: For @entity1 with @entity10479 , HPV testing was highly sensitive for detecting CIN3 and @entity5 with dramatically fewer referrals of older @entity1 . Neither a single HPV test nor repeat cytopathology provides useful triage for @entity1 with @entity2784 .

title: Effects of age and XXXX papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade @entity2784 Triage Study (ALTS).

entities_list: @entity10479 :: ('MESH:D065309', 'Disease') :: ['ASCUS', 'atypical squamous cells of undetermined significance']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV']

entities_list: @entity2784 :: ('MESH:D065310', 'Disease') :: ['LSIL', 'low-grade squamous intraepithelial lesions']

entities_list: @entity3146 :: ('MESH:D018290', 'Disease') :: ['Cervical Intraepithelial Neoplasia']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: Although protein kinases and phosphatases have been reported to be involved in fear memory, information about these signalling molecules in the individual phases of contextual fear conditioning (cFC) is limited. C57BL/6J @entity19 were tested in cFC, sacrificed and hippocampi were used for screening of approximately 800 protein kinases and phosphatases by protein microarrays with subsequent Western blot confirmation of threefold higher or lower hippocampal levels as compared to foot shock controls. Immunoblotting of the protein kinases and phosphatases screened out was carried out by Western blotting. A network of protein kinases and phosphatases was generated (STRING 9.1). Animals learned the task in the paradigm and protein kinase and phosphatase levels were determined in the individual phases acquisition, consolidation and retrieval and compared to foot shock controls. Protein kinases discoidin containing receptor 2 ( @entity25912 ), @entity10180 ( @entity10180 ), protein phosphatases dual specificity protein phosphatase ( @entity2370 ) and protein phosphatase 2a ( @entity21646 ) were modulated in the individual phases of cFC. @entity19065 3-phosphatase and @entity4357 -3 kinase (PI3K) that is interacting with @entity2370 were modulated as well. Freezing time was correlating with @entity21646 levels in the retrieval phase of cFC. The abovementioned protein kinases, phosphatases and @entity8580 -signalling enzymes were not reported so far in cFC and the results are relevant for interpretation of previous and design of future studies in cFC or fear memory. Protein phosphatase @entity21646 was, however, the only signalling compound tested that was directly linked to retrieval in the cFC.

title: Networks of protein kinases and phosphatases in the individual phases of contextual fear conditioning in the C57BL/6J XXXX .

entities_list: @entity19065 :: ('MESH:C060974', 'Chemical') :: ['Phosphatidyl-inositol-3,4,5-triphosphate']

entities_list: @entity8580 :: ('MESH:D007294', 'Chemical') :: ['inositol']

entities_list: @entity10180 :: ('26409(Tax:10090)', 'Gene') :: ['mitogen activated protein kinase kinase kinase 7', 'TAK1']

entities_list: @entity4357 :: ('MESH:D010716', 'Chemical') :: ['phosphatidylinositol']

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: A 43-year-old white @entity1 presented with an 8-month history of @entity4 . He also noted a decrease in range of motion of his upper body. There was no improvement with a 4-week course of topical corticosteroids. Review of systems was negative for @entity4683 , @entity2011 , @entity7298 , and @entity158 . His medical history included @entity308 , @entity354 , and microdiscectomy. His medications included @entity3756 and @entity4546 . Physical examination revealed a 20-cm erythematous, indurated plaque on the posterior part of the upper back and neck (Figure 1). A lack of skin wrinkling was noted with lateral pressure. Biopsy revealed a periadnexal and mild @entity1909 with an increase in connective tissue mucin as demonstrated with colloidal @entity68 (Figures 2A and 2B). Serum protein electrophoresis, hemoglobin @entity3916 , and antinuclear antibody titer were within normal limits. A diagnosis of @entity1252 mimicking @entity11387 was made. @entity6383 therapy was started at a dose of 200 mg and, at 2 months' follow-up, the @entity1 's symptoms and appearance were improved.

title: Tumid lupus erythematosus: an unusual XXXX -like presentation.

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity1909 :: ('MESH:D003872', 'Disease') :: ['interface dermatitis']

entities_list: @entity7298 :: ('MESH:D006963', 'Disease') :: ['polyphagia']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['redness and swelling on the back of the neck']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['tumid lupus erythematosus']

entities_list: @entity4683 :: ('MESH:D059606', 'Disease') :: ['polydipsia']

entities_list: @entity6383 :: ('MESH:D006886', 'Chemical') :: ['Hydroxychloroquine']

entities_list: @entity3756 :: ('MESH:D020280', 'Chemical') :: ['sertraline']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['bone pain']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['gastroesophageal reflux disease']

entities_list: @entity11387 :: ('MESH:D012592', 'Disease') :: ['scleredema']

entities_list: @entity4546 :: ('MESH:D009853', 'Chemical') :: ['omeprazole']

answer: @entity11387 :: (MESH:D012592,Disease) :: ['scleredema']


abstract: BACKGROUND: Discordance in hormone receptors (HR) and @entity1 @entity1722 ( @entity1722 ) status between primary @entity5 and metastatic sites for @entity0 is well established. However, it is uncertain which @entity1 -related factors lead to biopsy when @entity3 are suspected and whether having a biopsy impacts survival. METHODS: The medical charts of @entity0 ( @entity0 ) @entity1 diagnosed January 2000-August 2014 were retrospectively reviewed. A biopsy was defined as a procedure where tissue was obtained and assessed for both HR and @entity1722 . Both bivariate and multivariate analyses were performed to assess @entity1 characteristics related to biopsy and whether having a biopsy was associated with improved survival. RESULTS: Of 409 @entity1 suspected of having @entity0 , 165 (40%) had a biopsy, and 34% of these had discordant HR or @entity1722 status when compared to the initial diagnosis. In multivariate analysis, having a biopsy was associated with: recurrence in years 2010-2014, disease-free interval of   >   =3  years, stage 0-IIA at presentation, suspected locoregional recurrence, being HR+/ @entity1722 -, or missing HR/ @entity1722 at diagnosis. A similar multivariate analysis revealed that having a biopsy was associated with improved survival (HR   =   0.67, p   =   0.002). The association of biopsy and improved survival was noted in specific subgroups: @entity1 with missing HR and @entity1722 data at initial diagnosis (p   =   0.001), those without @entity3 in liver, lung or brain (p   =   0.001), and being younger than 70  years old at recurrence (p   <   0.001). CONCLUSIONS: Specific clinical factors were associated with biopsy at the time of suspected recurrence. Having a biopsy was associated with reduced mortality.

title: Biopsy of XXXX @entity3 : @entity1 characteristics and survival.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'metastatic breast cancer', 'MBC']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity1722 :: ('2064', 'Gene') :: ['epidermal growth factor receptor 2', 'HER2']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: OBJECTIVE: To evaluate the activities of the submental muscles using surface electromyography (sEMG) in @entity1 presenting with @entity1282 secondary to @entity2500 , and to compare the results with those in healthy volunteers. DESIGN: Retrospective study design. SETTING: A @entity1282 clinic at a tertiary care university hospital. @entity1 : Twenty-one @entity1 presenting with @entity1282 after @entity2500 were recruited into the study within 2 months of @entity64 onset. To serve as a control group, 13 healthy volunteers were enrolled. MAIN OUTCOME MEASURES: The primary sEMG parameters were swallowing onset, pretrigger duration, swallowing duration, and swallowing amplitude. Swallowing functional outcome was evaluated using the Videofluoroscopic @entity1282 Scale and the American Speech-Language-Hearing Association National Outcome Measurement System. RESULTS: @entity1 with @entity2500 demonstrated significantly delayed swallowing onset (P < .001) and shorter swallowing duration (P = .003) compared with the controls. Duration from the start of sEMG activity and actual laryngeal elevation also was delayed in the @entity1 group (P = .042). At a cut-off point of 0.13 seconds for swallowing onset, sensitivity was 85.7% and specificity was 69.2%. For swallowing duration, sensitivity was 84.6% and specificity was 66.7% with 1.05 seconds as the cut-off point. CONCLUSIONS: @entity1 with @entity2500 showed not only delayed swallowing onset and pretrigger duration, but also shorter duration of sEMG activity compared with those in healthy volunteers. Our results suggest that @entity1282 after @entity64 might be further compromised by delayed laryngeal response especially after the start of suprahyoid muscle activity, which represents impaired laryngeal protection mechanism.

title: Submental Muscle Activity is Delayed and Shortened During Swallowing Following XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PARTICIPANTS']

entities_list: @entity2500 :: ('MESH:D020244', 'Disease') :: ['MCA infarction', 'unilateral MCA infarction', 'middle cerebral artery (MCA) infarction']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['Dysphagia', 'dysphagia']

answer: @entity64 :: (MESH:D020521,Disease) :: ['Stroke']


abstract: The safety and efficacy of the two most widely used fixed-dose @entity507 -based combination therapies (ACT), artesunate-amodiaquine ( @entity68458 ) and artemether-lumefantrine (AL) are well established for single episodes of uncomplicated @entity3964 @entity311 , but the effects of repeated, long-term use are not well documented. We conducted a 2-year randomized, open-label, longitudinal, phase IV clinical trial comparing the efficacy and safety of fixed-dose @entity68458 and AL for repeated treatment of uncomplicated @entity311 in @entity1 under 5 years at Nagongera Health Centre, Uganda. @entity1 were randomized to @entity68458 or AL and all subsequent @entity311 episodes were treated with the same regimen. 413 @entity1 were enrolled and experienced a total of 6027 @entity311 episodes (mean 15; range, 1-26). For the first @entity311 episode, the PCR-corrected-cure rate for @entity68458 (97.5%) was non-inferior to that for AL (97.0%; 95% CI [-0.028; 0.037]). PCR-corrected cure rates for subsequent @entity311 episodes that had over 100 cases (episodes 2-18), ranged from 88.1% to 98.9% per episode, with no clear difference between the treatment arms. Parasites were completely cleared by day 3 for all @entity311 episodes and gametocyte carriage was less than 1% by day 21. Fever clearance was faster in the @entity68458 group for the first episode. Treatment compliance for subsequent episodes (only first dose administration observed) was close to 100%. Adverse events though common were similar between treatment arms and mostly related to the disease. Serious adverse events were uncommon, comparable between treatment arms and resolved spontaneously. @entity417 and @entity1398 occurred in <0.5% of cases per episode, @entity409 tests occurred in 0.3% to 1.4% of cases. Both regimens were safe and effective for repeated treatment of @entity311 . TRIAL REGISTRATION: Current Controlled Trials NCT00699920.

title: Efficacy and Safety of Fixed-Dose Artesunate-Amodiaquine vs. Artemether-Lumefantrine for Repeated Treatment of Uncomplicated Malaria in Ugandan XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Participants']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['abnormal liver function']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity507 :: ('MESH:C031327', 'Chemical') :: ['artemisinin']

entities_list: @entity3964 :: ('5833', 'Species') :: ['Plasmodium falciparum']

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: BACKGROUND; A significant phenotypical variability is observed in @entity8 ( @entity8 ), the most common @entity8 . @entity2232 ( @entity2232 ) has been suggested to be an important disease-promoting factor of the kidney. @entity17614 ( @entity17614 ) is the main protease responsible for @entity2232 generation by cleavage of its functionally inactive precursor. We examined the influence of the ECE-1b @entity61249 polymorphism on the progression of @entity8 toward @entity454 ( @entity454 ). The A allele was suggested to be associated with higher plasma level of @entity2232 . METHODS: 200 @entity8 @entity1 (107 males, 93 females) who had reached @entity454 were analyzed. @entity1 were divided into three groups: (1) 47 @entity1 (23 males, 24 females) with @entity454 later than in 63 yr (slow progressors); (2) 71 @entity1 (38 males, 33 females) with @entity454 before 45 yr (rapid progressors); and (3) 82 @entity1 (46 males, 36 females) with @entity454 between 45-63 yr. Moreover, we analyzed 160 genetically unrelated healthy Czech subjects as the control group (82 males, 78 females, mean age 51.4 +/- 8.2 yr). DNA samples from collected blood were genotyped for ECE-1b @entity61249 polymorphism using described polymerase chain reaction (PCR) followed by restriction enzyme digestion. We compared the frequencies of different genotypes between the groups of slow and rapid progressors and the ages of @entity454 with regard to different genotypes. RESULTS: The ECE-1b @entity61249 genotype distribution showed no differences among the groups of slow progressors, rapid progressors, @entity8 group with @entity454 between 45-63 yr and control group. Comparing the ages of @entity454 of all @entity1 , we did not find significant differences in the ages with regard to different genotypes: CC (51.5 +/- 10.1 yr), AC (51.6 +/- 11.4 yr), @entity5066 (48.2 +/- 5.9 yr). There was a tendency to lower age of @entity454 in @entity5066 homozygotes in comparison with other genotypes (t-test, p = 0.12). We found no influence of gender. CONCLUSION: We excluded the effect of ECE-1b @entity61249 polymorphism on the progression of @entity8 . We could observe a mild @entity177 in @entity5066 homozygous individuals.

title: The influence of the XXXX gene polymorphism on the progression of @entity8 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['ADPKD', 'autosomal dominant polycystic kidney disease', 'renal hereditary disease']

entities_list: @entity17614 :: ('1889', 'Gene') :: ['Endothelin-converting enzyme-1', 'ECE-1']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['tendency toward faster decline of renal function']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease', 'ESRD']

answer: @entity17614 :: (1889,Gene) :: ['endothelin-converting enzyme-1']


abstract: Cycling probe technology ( @entity1191 ) represents a simple method for detection of DNA target sequences. Cycling probe technology utilizes a chimeric DNA-RNA-DNA probe which is cleaved by RNase H when hybridized with its complementary target. Probe cleavage in the presence or absence of target generates @entity1191 product or background, respectively. Addition of non-homologous DNA into the @entity1191 reaction affects the background and @entity1191 product. Low amounts of @entity1 DNA (4-40 ng) result in high background while higher amounts (40-400 ng) inhibit the reaction. The simultaneous addition of @entity8037 and @entity4527 into the @entity1191 reaction containing @entity1 DNA resulted in a significant release of the inhibition and a reduction of background. The presence of @entity8037 alone caused an increase of probe cleavage whereas addition of EGTA increased the specificity of the @entity1191 . A possible mechanism by which @entity8037 could lead to this improvement of @entity1191 has been proposed. Using a membrane-binding assay, the authors demonstrated that @entity1 DNA competes with the probe for binding to RNase H. Furthermore, by using a DNA-agarose column, it has been shown that such RNase H-DNA binding can be disrupted by @entity8037 . Within the @entity1191 reaction, similar @entity8037 -mediated displacement of RNase H from @entity1 DNA could lead to an improved @entity1191 efficiency.

title: XXXX -mediated improvement of cycling probe reaction.

entities_list: @entity8037 :: ('MESH:D013096', 'Chemical') :: ['spermine']

answer: @entity8037 :: (MESH:D013096,Chemical) :: ['Spermine']


abstract: 1. Isolated longitudinal muscle-myenteric plexus preparations from @entity840 ileum were used to investigate the activity of myenteric neurons when the tissue was stretched in the circumferential direction. Membrane potentials were recorded via flexibly mounted intracellular recording electrodes containing @entity11480 in 1 M @entity4338 . The preparations were stretched to constant widths (+20% and +40% beyond slack width). 2. Multipolar neurons (Dogiel type II morphology) discharged spontaneous action potentials and proximal process potentials during maintained stretching, three of twenty-one at +20% stretch and seven of nine at +40% stretch. At the maximum extent of stretch tried, +40% beyond slack tissue width, action potentials in Dogiel type II neurons occurred at 10-33 Hz. Neurons with other morphologies were all uniaxonal. Some displayed spontaneous fast EPSPs or action potentials, three of forty one at +20% stretch and seven of nineteen at +40% stretch. 3. In seven of eight Dogiel type II neurons, action potentials or proximal process potentials persisted when membrane hyperpolarization was imposed via the recording electrode. Action potential discharge was abolished by hyperpolarization in seven of nine uniaxonal neurons; the exceptions were two orally projecting neurons. 4. Dogiel type II and uniaxonal neurons were classified as rapidly accommodating if they discharged action potentials only at the beginning of a 500 ms intracellular depolarizing pulse and slowly accommodating if they discharged for more than 250 ms. For Dogiel type II neurons, three of thirteen were slowly accommodating at +20% stretch and two of four at 40% stretch. For uniaxonal neurons the corresponding data were twelve of twenty-six and fifteen of nineteen neurons. The slowly accommodating state was associated with increased cell input resistance in uniaxonal neurons. 5. The spontaneous action potential discharge in Dogiel type II and uniaxonal neurons ceased when the muscle was relaxed pharmacologically by @entity3360 (3 microM) or @entity3044 (1 microM), although the applied stretch was maintained. At the same time, evoked spike discharge became rapidly accommodating. 6. We conclude that many Dogiel type II neurons, and possibly some orally projecting uniaxonal neurons, are intrinsic, stretch-sensitive, primary afferent neurons that respond to muscle tension with sustained action potential discharge.

title: Intracellular recording from myenteric neurons of the XXXX ileum that respond to stretch.

entities_list: @entity11480 :: ('MESH:C070614', 'Chemical') :: ['Neurobiotin']

entities_list: @entity3360 :: ('MESH:D009529', 'Chemical') :: ['nicardipine']

entities_list: @entity3044 :: ('MESH:D007545', 'Chemical') :: ['isoprenaline']

answer: @entity840 :: (10141,Species) :: ['guinea-pig']


abstract: STUDY OBJECTIVES: To determine the ability of quantitative CT, with special reference to area of @entity2415 , to predict early postoperative oxygenation capacity and outcome after lung lobectomy for @entity5 . METHODS: Sixty-two consecutive @entity1 scheduled to undergo lung lobectomy for @entity5 were enrolled in this study. The area of @entity2415 (< - 910 Hounsfield units) was measured on a three-dimensional CT lung model. Arterial @entity26 saturation (Sao(2)) was calculated from Pao(2) measured 1 day before and 1 day after surgery with @entity1 at rest breathing room air. A @entity1 was considered to have recovered at the completion of a standardized management regimen. RESULTS: Postoperative Sao(2) (postSao(2)) was predicted by the baseline value and the area of @entity2415 with the use of a regression equation. Ten of the 62 @entity1 (16%) had @entity260 (CPCs). The median time to postoperative recovery was 3 days (range, 1 to 17 days). Predicted postSao(2) and predicted postoperative FEV(1) were shown to be significant independent predictors of postoperative CPCs as well as postoperative recovery time. CONCLUSION: Determining the area of @entity2415 by quantitative CT is useful in predicting early postoperative oxygenation capacity. Predicted oxygenation capacity and predicted ventilatory capacity independently affect perioperative outcomes. Therefore, using quantitative CT in combination with spirometry may improve risk prediction in @entity1 undergoing lung lobectomy for @entity5 . However, the role of quantitative CT in grading nonemphysematous @entity358 , such as @entity401 , must be investigated.

title: Role of quantitative CT in predicting hypoxemia and complications after lung lobectomy for XXXX , with special reference to area of @entity2415 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative cardiopulmonary complications']

entities_list: @entity2415 :: ('MESH:D004646', 'Disease') :: ['emphysema']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['lung diseases']

entities_list: @entity401 :: ('MESH:D017563', 'Disease') :: ['interstitial lung diseases']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: BACKGROUND: RCAS1 is a recently discovered antigen molecule expressed on the membrane of @entity5 cells, and it acts as a ligand for a putative receptor present on immune cells such as T, B and NK cells. It has been suggested that RCAS1 expression is related to the escape of @entity5 from immune surveillance. In this study, the relation between RCAS1 expression and various clinicopathologic variables, including @entity1 prognosis, was investigated in @entity2 through immunohistochemical analysis. METHODS: One hundred two surgically resected @entity1149 cases were examined histopathologically by means of the monoclonal antibody 22-1-1, which is specific for RCAS1. The correlation between RCAS1 expression and the clinicopathologic features of @entity1 was evaluated. Moreover, the correlation between RCAS1 expression and the survival of @entity1 was analyzed by the Kaplan-Meier method log-rank test, and multivariate analysis was performed by using the Cox proportional hazard model. RESULTS: The samples of 48 of the 102 @entity2 @entity1 (47.1%) were positive for RCAS1. There were significant correlations between RCAS1 expression and either pathologic staging (P = 0.0003) or @entity5 differentiation (P = 0.0308). The survival time for the RCAS1-positive group was significantly shorter than that for RCAS1-negative group (P < 0.0001). Moreover, multivariate analysis for overall survival revealed that RCAS1 expression was a significantly independent prognostic factor in @entity1149 @entity1 . CONCLUSION: These results suggested that RCAS1 expression may play an important role in the immune escape mechanism and that RCAS1 expression may be a good indicator of poor prognosis in @entity1 with @entity1149 .

title: Expression of XXXX -associated antigen RCAS1 correlates significantly with poor prognosis in @entity1149 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung carcinoma']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['nonsmall cell lung carcinoma']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: UNASSIGNED: Purpose: @entity1 with @entity1614 require repeated imaging for monitoring of aortic root @entity439 . Therefore, we evaluated the agreement and reproducibility of cine-MRI and echocardiography measurements of the sinuses of Valsalva in @entity1 with suspected @entity1614 . Materials and Methods: 51 consecutive @entity1 with suspected @entity1614 were prospectively examined using cine-MRI and echocardiography. Two readers independently measured aortic root diameters at the level of the sinuses of Valsalva in both cine-MRI and echocardiography. Statistics included intraclass correlation coefficient, Pearson correlation coefficient, Bland-Altman analysis, and two-sided t-test. Results: In 38 of the 51 individuals (74.5%), the diagnosis of @entity1614 was established according to the criteria of the Ghent-2 nosology. Cine-MRI measurements of the sinuses of Valsalva revealed a strong correlation with echocardiography (r=0.929), but a statistically significant bias of -1.0mm (p<0.001). The mean absolute diameter for sinuses of Valsalva obtained by cine-MRI was 32.3  5.8mm as compared to 33.4  5.4mm obtained by echocardiography. Interobserver agreement of measurements of the sinuses of Valsalva was higher for cine-MRI than for echocardiography (p=0.029). Conclusion: Despite small, but statistically significant differences in terms of agreement and reproducibility, cine-MRI and echocardiographic measurements of aortic root diameters provide comparable results without a significant clinical difference. Therefore both techniques may be used for monitoring of the aortic root in @entity1 with @entity1614 . Key points:       Cine-MRI (ICC: 0.93, CI: 0.88-0.96) and echocardiography (ICC: 0.90, CI: 0.82-0.94) allow assessment of aortic root diameters in @entity1 with @entity1614      Cine-MRI offers higher reproducibility of aortic root diameters than echocardiography (95% limits of agreement of   3.6mm versus   5.0mm, p=0.029)      Aortic root measurements with cine-MRI and echocardiography reveal a small (mean difference; -1.0mm) but statistically significant offset (p=0.0004) Citation Format:       Bannas P., Rybczynski M., Sheikhzadeh S. etal. Comparison of Cine-MRI and Transthoracic Echocardiography for the Assessment of Aortic Root Diameters in @entity1 with Suspected Marfan Syndrome. Fortschr R  ntgenstr 2015; 187: 1022-1028.

title: Comparison of Cine-MRI and Transthoracic Echocardiography for the Assessment of Aortic Root Diameters in XXXX with Suspected Marfan Syndrome.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity1614 :: ('MESH:D008382', 'Disease') :: ['Marfan syndrome']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: The stratum corneum and DNA repair do not completely protect keratinocytes from ultraviolet B. A third defense prevents cells with DNA photoproducts from becoming precancerous mutant cells: apoptosis of ultraviolet-damaged keratinocytes ("sunburn cells"). As signals for ultraviolet-induced apoptosis, some studies implicate DNA photoproducts in actively transcribed genes; other studies implicate non-nuclear signals. We traced and quantitated the in vivo DNA signal through several steps in the apoptosis-signaling pathway in haired @entity19 . Homozygous inactivation of @entity24333 , @entity58361 , or @entity25971 nucleotide excision repair genes directed the accumulation of DNA photoproducts to specific genome regions. Repair-defective @entity24333 -/- @entity19 were 7-10-fold more sensitive to sunburn cell induction than wild-type @entity19 , indicating that 86-90% of the ultraviolet B signal for keratinocyte apoptosis involved repairable photoproducts in DNA; the remainder involves unrepaired DNA lesions or nongenomic targets. @entity58361 -/- @entity19 , defective only in excising photoproducts from actively transcribed genes, were as sensitive as @entity24333 -/-, indicating that virtually all of the DNA signal originates from photoproducts in active genes. Conversely, @entity25971 -/- @entity19 , defective in repairing the untranscribed majority of the genome, were as resistant to apoptosis as wild type. Sunburn cell formation requires the @entity186 @entity5 suppressor protein; 90-96% of the signal for its induction in vivo involved transcribed genes. @entity1231 , which regulates the stability of @entity186 through degradation, was induced in vivo by low ultraviolet B doses but was suppressed at erythemal doses. DNA photoproducts in actively transcribed genes were involved in approximately 89% of the @entity1231 response.

title: The DNA damage signal for @entity1231 regulation, XXXX induction, and sunburn cell formation in vivo originates from actively transcribed genes.

answer: @entity186 :: (22059(Tax:10090),Gene) :: ['Trp53']


abstract: BACKGROUND AND PURPOSE: Currently available stents for intracranial use usually are balloon-expandable coronary stents that carry the risk of damaging a @entity1347 , with potential vessel rupture. We assessed the technical feasibility and efficacy of the combined application of a flexible, self-expanding neurovascular stent and detachable coils in the management of wide-necked @entity438 in @entity1 . METHODS: Four consecutive @entity1 with a wide-necked @entity438 were treated with a combined approach that consisted of delivery of a flexible self-expanding neurovascular stent through a microcather to cover the neck of the @entity439 and subsequent filling of the @entity439 with coils through the stent interstices. The @entity439 were located at the internal carotid artery (n=2) and the basilar tip encroaching the P1 segment (n=2). Previous attempts with conventional endosaccular coil packing alone failed in all cases. RESULTS: Stent placement in the desired position with complete or nearly complete occlusion of the @entity439 was feasible in all @entity1 . In one @entity1 , @entity439 perforation with the microcatheter occurred and necessitated ventricular drainage, which led to a large parenchymal and @entity548 because of the strong anticoagulation regimen. Six-month follow-up demonstrated no focal neurologic sequelae in any of the @entity1 , except slight @entity2414 in the @entity1 with @entity548 . CONCLUSION: Preliminary data demonstrate that this extremely flexible stent is technically easy to deploy and can be easily and safely maneuvered through severely tortuous vessels, enabling the treatment of @entity438 . The combination of endovascular reconstruction of the parent vessel with use of a self-expanding stent followed by coil embolization offers a promising therapeutic alternative for wide-necked @entity439 not amenable to coil embolization alone. Although immediate angiographic results are promising, long-term angiographic and clinical follow-up is essential to determine permanent vessel patency and @entity439 rate.

title: Treatment of wide-necked XXXX with a self-expanding stent system: initial clinical experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'patients', 'patient']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['intraventricular hemorrhage', 'bleeding']

entities_list: @entity1347 :: ('MESH:C537775', 'Disease') :: ['dysplastic segment of the artery']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'aneurysm', 'aneurysm occlusion']

entities_list: @entity2414 :: ('MESH:D008569', 'Disease') :: ['memory dysfunction']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['intracranial aneurysm', 'intracranial wide-necked aneurysms', 'intracranial aneurysms']

answer: @entity438 :: (MESH:D002532,Disease) :: ['intracranial aneurysms']


abstract: Suppression of the secretion of @entity4090 , growth hormone and insulin-like growth factor 1 ( @entity442 ) might be important in the growth regulation and treatment of @entity0 . Because @entity2931 may counteract the anti- @entity5 effects of such treatment, the combination of an anti- @entity2931 ( @entity440 ), a @entity1943 analogue (octreotide) and a potent anti- @entity4090 (CV 205-502) might be attractive. In this respect, we performed a first exploratory long-term study on the feasibility of combined treatment and possible clear differences in endocrine and anti- @entity5 effects during such combined treatment vs standard treatment with @entity440 alone. Twenty-two post-menopausal @entity1 with metastatic @entity0 (ER and/or PR positive or unknown) were randomized to receive either 40 mg of @entity440 per day or the combination of 40 mg of @entity440 plus 75 microg of CV 205-502 orally plus 3 x 0.2 mg of @entity2390 s.c. as first-line endocrine therapy. An objective response was found in 36% of the @entity1 treated with @entity440 alone and in 55% of the @entity1 treated with combination therapy. Median time to progression was 33 weeks for @entity1 treated with @entity440 and 84 weeks for @entity1 treated with combination therapy, but the numbers are too small for hard conclusions. There was no difference in overall post-relapse survival between the two treatment arms. With respect to the endocrine parameters, there was a significant decrease of plasma @entity442 levels in both treatment arms, whereas during combined treatment plasma growth hormone tended to decrease and plasma @entity4090 levels were strongly suppressed; in some @entity1 insulin and @entity310 ( @entity7790 ) decreased during the triple therapy. Although there was no significant difference in mean decrease of plasma @entity442 levels between the two treatment arms, combined treatment resulted in a more uniform suppression of @entity442 . Therefore, the addition of a @entity1943 analogue and an anti- @entity4090 may potentially enhance the efficacy of anti- @entity2931 in the treatment of @entity0 owing to favourable endocrine and possible direct anti- @entity5 effects. Large phase III trials using depot formulations (to increase the feasibility) of @entity1943 analogues are warranted to demonstrate the potential extra beneficial anti- @entity5 effects of such combination therapy.

title: Feasibility, endocrine and anti- @entity5 effects of a triple endocrine therapy with XXXX , a @entity1943 analogue and an antiprolactin in post-menopausal metastatic @entity0 : a randomized study with long-term follow-up.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen']

entities_list: @entity2931 :: ('CHEBI:50114', 'Chemical') :: ['oestrogens', 'oestrogen']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity310 :: ('7124', 'Gene') :: ['transforming growth factor alpha']

entities_list: @entity2390 :: ('MESH:D015282', 'Chemical') :: ['octreotide']

entities_list: @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin']

answer: @entity440 :: (MESH:D013629,Chemical) :: ['tamoxifen']


abstract: Fetal and placental growth rate in @entity742 has been manipulated by removal of endometrial caruncles prior to conception. This produced two groups of fetuses, one in which prenatal growth rate was similar to normal and a second group in which the fetuses were about half of the normal size. The mortality in the latter group was high, particularly after catheterisation, and there was evidence of early @entity204 and fetal reabsorption. Prior to 125 days the relationship between fetal and placental size was poor, but after 126 days a close correlation between the two was apparent. The small fetuses had comparably small placentas and in all cases there was a close relationship between fetal and placental weight. The experimental @entity851 was associated with hypoglycaemia, @entity519 and hypoinsulinaemia. Plasma T3, T4 and particularly prolactin were very low in the small fetuses whilst levels of @entity701 and @entity493 were high. In contrast to the controls these fetuses showed little evidence of net @entity413 , @entity493 or @entity880 consumption. Infusion of 50% @entity413 into the pregnant ewe, sufficient to elevate maternal plasma @entity413 concentrations 2 to 3 fold, caused a comparable increase in the plasma concentrations of normal fetuses but only a 50% rise in the concentration in small fetuses. In contrast administration of 50% O2 to the ewes sufficient to cause a 2 to 3-fold increase in maternal @entity4095 caused only a small increase of arterial @entity4095 of normal fetuses but doubled that to normal levels in small fetuses. The results are discussed in relation to the effect of reduced placental size causing a fall in placental and transport and transport capacity and significance of this to the associated @entity1592 .

title: Studies on experimental XXXX in @entity742 . The effects of a small placenta in restricting transport to and growth of the fetus.

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['growth retardation']

entities_list: @entity1592 :: ('MESH:D005317', 'Disease') :: ['fetal growth retardation']

entities_list: @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['intra-uterine death']

entities_list: @entity493 :: ('CHEBI:16449', 'Chemical') :: ['alanine']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity851 :: (MESH:D006130,Disease) :: ['growth retardation']


abstract: @entity16451 is the etiological agent of a @entity2142 of @entity291 , known as anaplasmosis. The organism appears as a marginal inclusion in parasitized erythrocytes, but certain isolates also have bands associated with the inclusion. Inclusions and associated bands in parasitized erythrocytes in the liver and peripheral circulation were studied by light microscope cytochemistry and electron microscopy. Bands were comet- and dumbbell-shaped by light microscopy and were stained by techniques used to demonstrate protein and fibrin. The same forms, as well as other shapes, were seen in infected erythrocytes which were sectioned and examined by electron microscopy. Bands had longitudinal and transverse periodicity. They did not appear to have a crystalline structure. Their appearance was collated with that of @entity291 fibrin. Bands were well differentiated in erythrocytes that were entensively hemolyzed by natural or artificial means, but poorly differentiated in mildly hemolyzed erythrocytes. @entity2142 methods appeared to influence the morphology of bands and their demonstration.

title: The nature of bands in parasitized XXXX erythrocytes.

entities_list: @entity2142 :: ('MESH:D006461', 'Disease') :: ['Hemolysis', 'hemolytic disease']

entities_list: @entity16451 :: ('770', 'Species') :: ['Anaplasma marginale']

answer: @entity291 :: (9913,Species) :: ['bovine']


abstract: OBJECTIVE: @entity4236 and the management of @entity135 has posed considerable challenges to the treating physician. The aims of the study were to determine the incidence and factors influencing @entity135 and to identify at-risk @entity1 with cervical node-negative disease at presentation. STUDY DESIGN: Multicenter case series with retrospective chart review. SETTING AND SUBJECTS: In sum, 113 @entity1 with a histopathologic diagnosis of @entity4236 across 6 tertiary hospitals in Australia and the United States. METHODS: Treatment modalities for the primary site and neck included surgery, radiotherapy, and combined therapy. Treatment outcomes were measured in relation to date of primary treatment, and long-term follow-up was recorded. Disease-free survival was calculated as time for @entity1 to develop @entity135 following primary treatment. RESULTS: A total of 113 @entity1 (46 females, 49.7    13.2 years) were identified with a median follow-up of 41.5 months (interquartile range, 58.2); 7.1% of @entity1 presented with @entity135 , while 8.8% of @entity1 presented with @entity135 . @entity135 was present in @entity1 with Hyams grade II (22.2%), III (55.6%), and IV (22.2%) lesions (  (2) = 5.66, P = .13). Histologic grade was higher in @entity1 with @entity135 (  (2) = 16.22, P = .001). Positive surgical margins were associated with a higher risk of @entity135 as compared with clear surgical margin (17.9% vs 5%, P = .034). CONCLUSION: Neck metastasis is an important clinical consideration for @entity4236 at presentation and in surveillance. Primary treatment of the neck could be considered in select @entity1 . Long-term surveillance of the neck and primary site is essential.

title: XXXX : Fate of the Neck-A Long-term Multicenter Retrospective Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4236 :: ('MESH:D018304', 'Disease') :: ['olfactory neuroblastoma', 'Olfactory neuroblastoma']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['delayed neck disease', 'primary neck disease', 'Neck disease', 'neck disease']

answer: @entity4236 :: (MESH:D018304,Disease) :: ['Olfactory Neuroblastoma']


abstract: The antitumor effects of Corynebacterium parvum in a @entity19 @entity43 model depend upon a sequential activation of neutrophils and macrophages within the peritoneal cavity. We studied the sequential administration of biological response modifiers that independently activate each phase of the response. Tumor-challenged @entity19 treated by i.p. injection of a @entity4605 -extracted fraction of cell-free @entity5478 (PA-PE, 1400 micrograms) demonstrated prolonged survival in less than 20% of the cases. An i.p. injection of a detoxified Salmonella endotoxin (DSE) preparation (150 micrograms) had no effect on @entity5 outgrowth. However, i.p. treatment with PA-PE (1400 micrograms), followed by 150 micrograms of DSE 1 day later, resulted in long-term survival (greater than 100 days) in 40 to 60% of mice. This antitumor effect was only evident when PA-PE was administered first (before DSE) and optimal when DSE was administered 24 h after PA-PE. The synergistic antitumor effect could be duplicated when @entity5 -challenged @entity19 were first treated i.p. with peritoneal polymorphonuclear leukocytes, elicited by injection of PA-PE, and then treated with DSE 18 h later. These data indicate that appropriately timed injection of biological response modifiers with complementary effects can result in a synergistic prevention of @entity5 growth.

title: Synergistic effects of combination sequential immunotherapies in a XXXX @entity43 model.

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian teratocarcinoma']

entities_list: @entity4605 :: ('MESH:C023666', 'Chemical') :: ['pyridine']

entities_list: @entity5478 :: ('1747', 'Species') :: ['Propionibacterium acnes']

answer: @entity19 :: (10090,Species) :: ['murine']


abstract: The purpose of this study is to evaluate the effects of @entity1363 on circulation, respiration, sedation, and liver function of the neonates. The study subjects are 27 neonates (body weight 2.1 to 3.8 kg, gestational age at birth 34 to 41 weeks) who underwent surgery in neonatal period. Of 27, 13 @entity1 received @entity3303 (1.5 mg.kg-1) immediately before tracheal intubation (group L), and 14 had @entity1363 (0.1 mg.kg-1) with @entity3303 (group ML). We compared the effects of @entity1363 in the presence of @entity3303 on the following parameters: (1) the incidence of @entity551 (systolic blood pressure < 50 mmHg) and @entity1168 (heart rate < 100 beats. @entity1009 ), (2) the incidence of @entity386 and desaturation of @entity26 (< 80%), (3) the degree of sedation, and (4) the serum levels of @entity648 and unbound @entity648 after surgery. In group L, there were @entity551 (1/13) and desaturation (1/13). In group ML, there were desaturation (1/14) and post-operative @entity386 (1/14). None in both groups developed @entity1168 or @entity932 . A single-dose of @entity3303 induced sedation only in 4 neonates, while combination of @entity1363 and @entity3303 in 11. None had elevation of either total or unbound @entity648 after surgery. In conclusion, the titrated dose of @entity1363 with @entity3303 is useful for anesthetic induction of neonates, although cares should be taken on its adverse effects such as @entity551 , desaturation, and post-operative @entity386 .

title: [ XXXX for anesthetic induction in neonates].

entities_list: @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial hemorrhage']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity1363 :: ('MESH:D008874', 'Chemical') :: ['midazolam']

answer: @entity1363 :: (MESH:D008874,Chemical) :: ['Midazolam']


abstract: OBJECTIVE: To determine the management of @entity1 with new onset @entity2210 by Canadian family physicians. METHODS: A survey was mailed to 195 family physicians in August 1995 to identify how they manage @entity2210 in @entity1 according to four scenarios: based on presenting symptoms alone; assuming @entity1534 -positive; known to be @entity1534 -negative; and endoscopically confirmed @entity2210 . RESULTS: A total of 170 of 195 physicians (87.2%) completed the survey. Physicians reported that 7.3% of their practice is devoted to @entity2210 and 23% of these dyspeptic @entity1 present for the first time. Ninety-three per cent of family physicians find a symptom classification of ulcer-, reflux- and @entity4423 -like @entity2210 helpful. The majority of @entity1 are advised to make life-style changes and are treated with antacids or empiric drug therapy. A H2 receptor antagonist was the drug of choice for @entity1066 , while prokinetics were often used for reflux and @entity4423 -like @entity2210 . After failure of initial treatment, @entity1 were given another course of empiric treatment, commonly with @entity4392 or @entity4546 . Family physicians estimated that the mean time to obtain a gastrointestinal consult was five weeks, and 70% indicated that this time to consult adversely influenced their decision to refer. If this time was reduced to less than two weeks, responding physicians would consider referring all eligible @entity1 . On average, two to 2.5 courses of empiric therapy were given before referral. If @entity1534 status was known, fewer empiric treatments (mean 1.8) were given before gastroenterological referral compared with the other scenarios. If the @entity1 had @entity2210 , 30% of family physicians provided reassurance only and did not prescribe empiric drug treatment. CONCLUSIONS: Most newly dyspeptic @entity1 in Canada are treated with empiric therapy according to symptom classification and referred for endoscopy after an average two to 2.5 treatment courses.

title: A Canadian physician survey of XXXX management.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity4392 :: ('MESH:D020117', 'Chemical') :: ['cisapride']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer and reflux-like dyspepsia']

entities_list: @entity1534 :: ('210', 'Species') :: ['H pylori', 'Helicobacter pylori']

entities_list: @entity2210 :: ('MESH:D004415', 'Disease') :: ['dyspepsia', 'nonulcer dyspepsia']

entities_list: @entity4423 :: ('MESH:D015154', 'Disease') :: ['dysmotility']

entities_list: @entity4546 :: ('MESH:D009853', 'Chemical') :: ['omeprazole']

answer: @entity2210 :: (MESH:D004415,Disease) :: ['dyspepsia']


abstract: @entity7766 has been recently characterised as one of the strongest circulating vasoconstrictor peptides, its elevated level may cause @entity3361 and increase of peripheral vascular resistance. All this contributes to @entity63 @entity296 and decrease of regional and global left ventricular function. The aim of the study was the examination of @entity7766 plasma levels in @entity1 with @entity583 ( @entity583 ) after thrombolytic therapy with or without reperfusion. The survey was made in 82 @entity1 with @entity583 after thrombolytic therapy: 40 of them without reperfusion and 42 with reperfusion. The control group consisted of 20 healthy @entity1 . Plasma levels of @entity7766 were measured before thrombolysis, then 1, 3 and 5 days after, using a radioimmunologic method. All @entity1 were treated with @entity117 , @entity1242 and thrombolytic therapy (TT) with alteplase (r-TPA). In @entity1 with @entity583 , @entity7766 plasma levels were normal before and 1 day after TT, and were significant elevated 3 days after TT 5 days after TT, plasma @entity7766 levels were still high in @entity1 without reperfusion, but they decreased in @entity1 with reperfusion. There was significant negative correlation between @entity7766 level and left ventricular ejection fraction measured 5 days after @entity583 . During 30-days follow up @entity299 of left ventricle with ejection fraction under 40% occurred in 21 @entity1 and in 11 of them clinical symptoms of @entity712 were observed. Using the multivariable regression analysis we showed that @entity7766 concentration over 60 pg/ml is the independent factor leading to @entity299 . The results of our study suggest the contribution of @entity7766 to the left ventricular remodeling after @entity583 .

title: [Plasma levels of neuropeptide Y i XXXX with current @entity583 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'persons']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial damage']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity7766 :: ('4852', 'Gene') :: ['NPY', 'Neuropeptide Y (NPY)']

entities_list: @entity1242 :: ('MESH:D005996', 'Chemical') :: ['glyceryl trinitrate']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin']

entities_list: @entity3361 :: ('MESH:D003329', 'Disease') :: ['coronary artery spasm']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['systolic dysfunction', 'left ventricle systolic dysfunction']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Left and right @entity694 can display different clinical, pathologic, and genetic characteristics. The purpose of this study was to characterize multiple molecular genetic alterations in sporadic @entity694 and to correlate them with the location of the @entity5 and with lymph node @entity3 . METHODS: One hundred and twenty-five cases of sporadic @entity694 (50 in the right colon and 75 in the left colon in @entity1 with no family history of @entity694 ) were studied. Status of the @entity876 gene was assessed by polymerase chain reaction (PCR), single strand conformation polymorphism, and sequencing at exons 5-8. @entity124 was analyzed with five microsatellite markers at chromosome 18. The mismatch repair genes @entity6756 and @entity4311 were studied in @entity5 found to have microsatellite instability by PCR and sequencing. RESULTS: In the 125 cases studied, there were 53 @entity5 with mutations of the @entity876 gene. @entity876 mutations correlated with lymph node @entity3 from right @entity694 cases (61%), and all cases with @entity876 mutations and microsatellite instability were AJCC/UICC Stage III (Dukes Stage C). In the right @entity694 cases the rate of microsatellite instability was related to the @entity5 size (19% in @entity5 measuring < 4 cm, and 34% in @entity5 measuring > 4 cm). No correlation between microsatellite instability and @entity876 mutations was detected. In the left @entity694 cases, @entity876 mutations were detected in 41% of @entity5 and microsatellite instability in 14%; neither finding was related to the @entity5 size. Mutations of the @entity6756 and @entity4311 mismatch repair genes were detected in 7 of 24 cases with marked microsatellite instability. CONCLUSIONS: @entity124 is prone to occur in sporadic right @entity694 during @entity5 growth and is not associated significantly with mutations in the @entity6756 and @entity4311 mismatch repair genes or in the @entity876 gene. Concomitant detection of microsatellite instability and @entity876 mutations in right @entity694 is associated with the presence of lymph node @entity3 .

title: @entity124 and XXXX mutations in sporadic right and left @entity694 : different clinical and molecular implications.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity124 :: ('MESH:D053842', 'Disease') :: ['Microsatellite instability']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon carcinomas', 'colon carcinoma']

answer: @entity876 :: (7157,Gene) :: ['p53']


abstract: In order to explore the interactions between @entity4212 and @entity7895 , in silico methodologies such as docking and 3D-QSAR were performed. CoMFA and CoMSIA analyses were done using ligand based and receptor guided alignment schemes. Validation statistics include leave-one-out cross-validated R(2) (q(2)), internal prediction parameter by progressive scrambling (Q(*2)), external prediction with test set. They show that models derived from this study are quite robust. Ligand based CoMFA (q(2) = 0.747, Q(*2) = 0.639, r(pred)(2)=0.802) and CoMSIA model (q(2) = 0.810, Q(*2) = 0.676, r(pred)(2)=0.785) were developed using atom by atom matching. Receptor guided CoMFA (q(2) = 0.712, Q(*2) = 0.497, r(pred)(2) = 0.841) and for CoMSIA (q(2) = 0.805, Q(*2) = 0.589, r(pred)(2) = 0.937) models were developed by docking of highly active @entity19317 into the proposed NBD ( @entity377 binding domain) of @entity7895 . The 3D-QSAR models generated here predicted that hydrophobic and steric parameters are important for activity toward @entity7895 . Our studies indicate the important @entity535 in NBD crucial for binding in accordance with the previous results. This site forms a hydrophobic site. Since @entity3088 have potential without @entity137 , we propose to inspect this hydrophobic site including @entity2734 1043 and @entity2574 1049 should be considered for future inhibitor design.

title: Docking and 3D-QSAR (quantitative structure activity relationship) studies of XXXX , the potent inhibitors of p-glycoprotein targeting the @entity377 binding domain.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity4212 :: ('MESH:D047309', 'Chemical') :: ['flavones']

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

entities_list: @entity3088 :: ('MESH:D005419', 'Chemical') :: ['flavonoids']

answer: @entity4212 :: (MESH:D047309,Chemical) :: ['flavones']


abstract: 1. @entity1812 promotes @entity528 and @entity2657 through the activation of the B(2) receptor. The neuroprotective effect of LF 16-0687 Ms, a B(2) receptor antagonist, has been described when given prior to induction of transient focal @entity2806 in @entity35 , but there are no data regarding the consequence of a treatment when given after injury. Therefore, in a @entity19 model of transient @entity2500 ( @entity2500 ), we evaluated the effect of LF 16-0687 Ms given prior to and/or after the onset of @entity63 on @entity51 , @entity1188 volume and inflammatory responses including @entity2657 , blood-brain barrier (BBB) disruption and neutrophil accumulation. 2. LF 16-0687 Ms (1, 2 and 4 mg kg(-1)) administered 0.5 h before and, 1.25 and 6 h after @entity2500 , decreased the @entity1188 volume by a maximum of 33% and significantly improved the neurological recovery. 3. When given at 0.25 and 6.25 h after @entity2500 , LF 16-0687 Ms (1.5, 3 and 6 mg kg(-1)) decreased the @entity1188 volume by a maximum of 25% and improved the neurological score. 4. Post-treatment with LF 16-0687 Ms (1.5 mg kg(-1)) significantly decreased @entity2657 (-28%), BBB disruption (-60%) and neutrophil accumulation (-65%) induced by @entity63 . Physiological parameters were not modified by LF 16-0687 Ms. 5. These data emphasize the role of @entity1812 B(2) receptor in the development of @entity4798 , @entity51 and inflammatory responses resulting from transient focal @entity2806 . Therefore, B(2) receptor antagonist might represent a new therapeutic approach in the pharmacological treatment of @entity64 .

title: LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces @entity2806 in a @entity19 model of transient focal XXXX .

entities_list: @entity4798 :: ('MESH:D020520', 'Disease') :: ['infarct lesion']

entities_list: @entity2657 :: ('MESH:D001929', 'Disease') :: ['cerebral edema', 'brain edema']

entities_list: @entity2806 :: ('MESH:D002545', 'Disease') :: ['cerebral ischemia']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity2500 :: ('MESH:D020244', 'Disease') :: ['middle cerebral artery occlusion', 'MCAO']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficit']

entities_list: @entity1812 :: ('MESH:D001920', 'Chemical') :: ['Bradykinin', 'bradykinin']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal damage']

answer: @entity2806 :: (MESH:D002545,Disease) :: ['cerebral ischemia']


abstract: BACKGROUND: @entity129 is a potentially devastating complication following @entity572 . The purpose of this study was to retrospectively identify risk factors for, and the prognosis associated with, a @entity129 following primary @entity572 . METHODS: Between 1970 and 2000, 27,004 primary total hip arthroplasties were performed at our institution. Forty-seven @entity1 (0.17%) with @entity86 were identified by a review of the complications log of a total joint database. The medical record of each @entity1 provided the data for this study. The average age of the @entity1 was fifty-seven years at the time of surgery. The @entity1 had serial clinical examinations for a minimum of two years, or until neurologic recovery or death. The @entity129 were classified as complete or incomplete, and only @entity1 with objective motor weakness were included in the study. The limb lengths were measured on preoperative and postoperative radiographs, and those data were then compared with the limb lengths in a matched cohort of @entity1 who had not sustained a @entity128 after a primary @entity572 . The extent of neurologic recovery, the need for braces or walking aids, and the use of medications for @entity158 were evaluated. RESULTS: There were twenty-nine complete @entity129 (sixteen peroneal, eleven sciatic, and two femoral) and eighteen incomplete @entity129 (fourteen peroneal, three sciatic, and one femoral). A preoperative diagnosis of @entity572 (p = 0.0004) or posttraumatic @entity625 (p = 0.01), the use of a posterior approach (p = 0.032), lengthening of the extremity (p < 0.01), and cementless femoral fixation (p = 0.03) were associated with a significantly increased odds ratio for the development of a postoperative @entity129 . Of the twenty-eight @entity1 with a complete palsy who were available for follow-up, only ten (36%) had complete recovery of motor strength, which took an average of 21.1 months. Seven of the eighteen @entity1 with an @entity912 fully recovered their preoperative strength. Twenty-one @entity1 required walking aids, and fifteen required permanent use of an ankle-foot orthosis. Five @entity1 required daily medication for chronic @entity158 . CONCLUSIONS: @entity129 is uncommon following primary @entity572 . A preoperative diagnosis of @entity572 or posttraumatic @entity625 , the use of a posterior approach, lengthening of the extremity, and use of an uncemented femoral implant increased the odds ratio of sustaining a @entity129 . The majority of the @entity2103 in our series, whether complete or incomplete, did not fully resolve.

title: XXXX following primary @entity572 .

entities_list: @entity129 :: ('MESH:D003389', 'Disease') :: ['Motor nerve palsy', 'Nerve palsy', 'nerve palsies', 'motor nerve palsies', 'motor nerve palsy']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity128 :: ('MESH:D020209', 'Disease') :: ['nerve injury']

entities_list: @entity2103 :: ('MESH:D005155', 'Disease') :: ['motor nerve deficits']

entities_list: @entity572 :: ('MESH:D006617', 'Disease') :: ['total hip arthroplasty', 'developmental dysplasia of the hip']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative motor nerve dysfunction']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['neurogenic pain']

entities_list: @entity912 :: ('MESH:D010243', 'Disease') :: ['incomplete palsy']

answer: @entity129 :: (MESH:D003389,Disease) :: ['Motor nerve palsy']


abstract: Eleven @entity1 treated at the University of Texas M. D. Anderson @entity5 Center for recurrent disease after resection of a stage I @entity43 of low malignant potential (SNLMP) are reported. At the time of diagnosis, the age of the @entity1 ranged from 26 to 43 years (mean 33). Seven @entity1 had stage IB @entity5 and 4 had stage IA @entity5 . All @entity1 were treated with a total abdominal hysterectomy and bilateral salpingo-oophorectomy. The size of the @entity43 ranged from 4 to 15 cm in maximum dimension. Stromal microinvasion was seen in 2 cases, and foci of @entity14708 were seen in the peritoneum in 8 cases. Nine @entity1 were treated with radiotherapy and 2 with chemotherapy. The time to recurrent disease ranged from 7 to 39 years (mean 16). @entity5 recurred in the pelvis or abdomen, 2 in the neck with subsequent abdominal involvement, and 1 in the pleura without abdominal or pelvic involvement. In 10 cases, the recurrent @entity5 were @entity189 , and in 1 case it was a SNLMP. Recurrences were treated with chemotherapy in 10 cases and with hormones in 1 case. Seven @entity1 died of progressive @entity189 2 to 5 years after the recurrence. One @entity1 died of @entity1778 with recurrent @entity43 10 years after the recurrence was detected. Two @entity1 are alive with progressive disease 1 and 7 years after the recurrence, and 1 @entity1 whose disease recurred as a SNLMP is alive with no evidence of disease 9 years after the recurrence. These 11 @entity1 were compared with 16 @entity1 who had stage I ovarian SNLMPs that did not recur after a minimum follow-up of 15 years. There was no difference in the age of the @entity1 , gravidity, size of the @entity5 , or several microscopic parameters, including degree of epithelial proliferation, number of mitoses, and nuclear atypia. Microinvasion was found in one case. The only significant difference between the two groups was the low frequency of @entity14708 in the cases that had no disease recurrences (12.5% versus 72.7%). In summary, we found no clinical or pathologic features that can unequivocally predict the recurrence of stage I ovarian SNLMPs. Because of the long interval to recurrence, the fact that the recurrent @entity5 in 10 of 11 @entity1 were @entity189 , and the result of the X-chromosome inactivation in one case, the recurrent @entity5 could represent independent primaries or a slow progression of one clone present in the SNLMPs.

title: @entity5 recurrence in XXXX of low malignant potential.

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian tumors', 'ovarian tumor', 'ovarian serous neoplasm']

entities_list: @entity14708 :: ('MESH:C537064', 'Disease') :: ['endosalpingiosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Eight tumors', 'Cancer', 'tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['serous carcinomas', 'serous carcinoma']

answer: @entity43 :: (MESH:D010051,Disease) :: ['stage I ovarian serous neoplasms']


abstract: UNASSIGNED: Limited research exists on how different oil types and time of addition affect starch digestibility of @entity579 . This study aimed to assess the starch digestibility of white and @entity23420 prepared with 2 oil types: vegetable oil (unsaturated fat) and ghee (clarified butter, saturated fat) added at 3 different time points during the cooking process ("before": frying raw @entity579 in oil before boiling, "during": adding oil during boiling, and "after": stir-frying cooked @entity579 in oil). @entity23420 produced a slower digestion rate than white @entity579 . White @entity579 digestibility was not affected by oil type, but was affected by addition time of oil. Adding oil "after" (stir-frying) to white or @entity23420 resulted in higher slowly digestible starch. @entity23420 cooked using ghee showed the lowest amount of @entity413 release during in vitro digestion. The addition of ghee "during" (that is boiling with ghee) or "before" (that is frying @entity579 raw with ghee then boiling) cooking showed potential for attenuating the postprandial glycemic response and increasing resistant starch content. This is the first report to show healthier ways of preparing @entity579 . White @entity579 with oil added "after" (stir-fried) may provide a source of sustained @entity413 and stabilize blood @entity413 levels. Boiling @entity23420 with ghee or cooking @entity23420 with ghee pilaf-style may provide beneficial effects on postprandial blood @entity413 and insulin concentrations, and improve colonic health. The encouraging results of the present study justify extending it to an in vivo investigation to conclusively determine the effect of time of addition of fat when @entity579 is cooked on blood @entity413 homeostasis.

title: The Glycemic Potential of White and XXXX Affected by Oil Type and Time of Addition.

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity23420 :: (4529,Species) :: ['Red Rice']


abstract: UNASSIGNED: We aimed to characterize genotype-phenotype correlations and establish baseline clinical data for @entity1897 caused by mutations in the @entity32852 ( @entity32852 ) gene. @entity32852 mutations are the second leading cause of @entity5108 . Recent research makes clinical trials for @entity1 with @entity32852 mutations a realistic possibility. However, the clinical severity varies with different mutations and natural history data on progression is sparse. We present cross-sectional data to begin to define the phenotypic spectrum and clinical baseline of @entity1 with these mutations. A cohort of @entity1 with @entity32852 gene mutations was identified in 13 centres of the @entity74 Consortium - Rare Disease Clinical Research Consortium (INC-RDCRC) between 2009 and 2012 and at Wayne State University between 1996 and 2009. @entity1 phenotypes were quantified by the @entity16 score version 1 or 2 and the @entity5108 paediatric scale outcome instruments. Genetic testing was performed in all @entity1 and/or in first- or second-degree relatives to document mutation in @entity32852 gene indicating diagnosis of @entity5108 . There were 103 @entity1 from 71 families with 47 different @entity32852 mutations with a mean age of 40 years (range 3-84 years). @entity1 and mutations were separated into infantile, childhood and adult-onset groups. The infantile onset group had higher @entity16 score version 1 or 2 and slower nerve conductions than the other groups, and severity increased with age. Twenty-three @entity1 had no family history of @entity5108 . Sixty-one @entity1 wore foot/ankle orthoses, 19 required walking assistance or support, and 10 required wheelchairs. There was @entity393 in 21 and @entity1635 in 17. Forty-two @entity1 did not begin walking until after 15 months of age. Half of the infantile onset @entity1 then required ambulation aids or wheelchairs for ambulation. Our results demonstrate that virtually all @entity32852 mutations are associated with specific phenotypes. Early onset (infantile and childhood) phenotypes likely represent developmentally impaired myelination, whereas the adult-onset phenotype reflects @entity528 without antecedent @entity17 . Data from this cohort of @entity1 will provide the baseline data necessary for clinical trials of @entity1 with @entity5108 caused by @entity32852 gene mutations.

title: Genotype-phenotype characteristics and baseline natural history of heritable XXXX caused by mutations in the @entity32852 gene.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient']

entities_list: @entity17 :: ('MESH:D003711', 'Disease') :: ['demyelination']

entities_list: @entity5108 :: ('MESH:D002607', 'Disease') :: ['Charcot-Marie-Tooth disease type 1B', 'Charcot-Marie-Tooth disease type 1', 'Charcot-Marie-Tooth disease']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['Charcot-Marie-Tooth disease neuropathy']

entities_list: @entity1635 :: ('MESH:D012600', 'Disease') :: ['scoliosis']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral neuropathies']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['Inherited Neuropathies']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['axonal degeneration']

entities_list: @entity32852 :: ('4359', 'Gene') :: ['myelin protein zero', 'MPZ']

answer: @entity16 :: (MESH:D009422,Disease) :: ['neuropathies']


abstract: The penetration of blood vessels in the @entity267 causes a reduction of transparency and as a @entity227 or even @entity1939 . MATERIALS AND METHODS: Experiments were conducted on 120 New Zealand albino @entity95 , separated into different groups. Doses of vasculogenic alkalis provoked burning of the corneas. The following methods were used: Split-lamp investigation of the @entity267 with @entity941 , @entity941 angiography of the corneal neovessels, light and electron microscopy. Left eyes served as a control. Right eyes were treated with heparin and @entity1667 , @entity5303 , prooxygens and antioxidants. RESULTS: Application of heparin and @entity1667 reversibly inhibited the process of neoangiogenesis but intensified the corneal ulcer. The application of @entity5303 stimulated angiogenesis in the @entity267 . Electron microscopic observations showed the generation of transport pathways through the walls of neovessels. The basement membrane of the neovessels was formed nearly 4 - 5 months after their growth. @entity941 angiography showed first increased permeability from the walls of the neovessels and, 4 - 5 months later, poor penetration of the @entity941 through the vessels walls. CONCLUSIONS: The application of inhibitors of neoangiogenesis decreases the repair processes in corneal lesions with initial @entity2295 . The angiogenic factors are distributed by diffusion in the @entity2687 and neovessels initiate from the nearest limbic vessels. With the support of @entity941 angiography we can specify the time of their formation. The process of regression of the neovessels should be investigated.

title: [Neovascularisation of the XXXX ].

entities_list: @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['result reduced vision']

entities_list: @entity5303 :: ('MESH:C018021', 'Chemical') :: ['cobalt dichloride']

entities_list: @entity2295 :: ('MESH:D015861', 'Disease') :: ['neovascularization']

entities_list: @entity1939 :: ('MESH:D001766', 'Disease') :: ['blindness']

entities_list: @entity2687 :: ('MESH:D003316', 'Disease') :: ['corneal stroma']

entities_list: @entity941 :: ('MESH:D019793', 'Chemical') :: ['Fluorescein', 'fluorescein']

answer: @entity267 :: (MESH:D065306,Disease) :: ['cornea']